Journal of Headache and Pain

Papers
(The TQCC of Journal of Headache and Pain is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Identification of disease- and headache-specific mediators and pathways in migraine using blood transcriptomic and metabolomic analysis458
Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment i228
Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis148
The International Headache Congress – IHS and EHF joint congress 2021: late breaking abstracts108
Calcitonin gene-related peptide-targeting drugs and Raynaud’s phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database103
Development and validation of a novel model for characterizing migraine outcomes within real-world data96
Real-World experience of interictal burden and treatment in migraine: a qualitative interview study94
Episodic headache with spontaneous hypothermia reveal Shapiro’s syndrome variant with effectiveness of clonidine therapy86
Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy78
Tracking tDCS induced grey matter changes in episodic migraine: a randomized controlled trial71
CGRP-dependent sensitization of PKC-δ positive neurons in central amygdala mediates chronic migraine63
Interictal osmophobia is associated with longer migraine disease duration61
MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention59
Galcanezumab effect on “whole pain burden” and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experience56
Migraine susceptibility is modulated by food triggers and analgesic overuse via sulfotransferase inhibition55
Altered functional connectivity of the right caudate nucleus in chronic migraine: a resting-state fMRI study53
Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(−receptor) antibodies51
The headache registry of the German Migraine and Headache Society (DMKG): baseline data of the first 1,351 patients50
Migraine-relevant sex-dependent activation of mouse meningeal afferents by TRPM3 agonists50
Long term evaluation of a multidisciplinary trigeminal neuralgia service47
Altered effective connectivity in migraine patients during emotional stimuli: a multi-frequency magnetoencephalography study47
The economic and personal burden of cluster headache: a controlled cross-sectional study47
Interleukin-6 induces spatially dependent whole-body hypersensitivity in rats: implications for extracephalic hypersensitivity in migraine46
Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months46
Altered speech patterns in subjects with post-traumatic headache due to mild traumatic brain injury44
Enhanced functional connectivity between habenula and salience network in medication-overuse headache complicating chronic migraine positions it within the addiction disorders: an ICA-based resting-st44
Sphingosine-1 phosphate receptor 1 contributes to central sensitization in recurrent nitroglycerin-induced chronic migraine model43
Migraine patients in Germany - need for medical recognition and new preventive treatments: results from the PANORAMA survey41
Shift from high-frequency to low-frequency episodic migraine in patients treated with Galcanezumab: results from two global randomized clinical trials40
Osmophobia in primary headache patients: associated symptoms and response to preventive treatments40
Whole-brain morphological alterations associated with trigeminal neuralgia39
Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance39
Single-Pulse Transcranial Magnetic Stimulation for the preventive treatment of difficult-to-treat migraine: a 12-month prospective analysis37
Correction to: Migraine-relevant sex-dependent activation of mouse meningeal afferents by TRPM3 agonists37
Cerebral perfusion variance in new daily persistent headache and chronic migraine: an arterial spin-labeled MR imaging study37
Correction to: Burden of migraine and unmet needs from the patients’ perspective: a survey across 11 specialized headache clinics in Korea36
Burden of tension-type headache in the Middle East and North Africa region, 1990-201935
Correction to: CGRP induces migraine-like symptoms in mice during both the active and inactive phases35
Understanding the link between obesity and headache- with focus on migraine and idiopathic intracranial hypertension34
Post-traumatic trigeminal neuropathy: correlation between objective and subjective assessments and a prediction model for neurosensory recovery34
Manual joint mobilisation techniques, supervised physical activity, psychological treatment, acupuncture and patient education for patients with tension-type headache. A systematic review and meta-ana33
Is there a causal relationship between stress and migraine? Current evidence and implications for management32
Functional correlation of ATP1A2 mutations with phenotypic spectrum: from pure hemiplegic migraine to its variant forms31
Coronavirus disease-19 and headache; impact on pre-existing and characteristics of de novo: a cross-sectional study31
Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II29
Real-world experience with 240 mg of galcanezumab for the preventive treatment of cluster headache29
HMGB1, NLRP3, IL-6 and ACE2 levels are elevated in COVID-19 with headache: a window to the infection-related headache mechanism29
Altered amygdala effective connectivity in migraine without aura: evidence from resting‐state fMRI with Granger causality analysis28
European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update28
In search of a gold standard patient-reported outcome measure to use in the evaluation and treatment-decision making in migraine prevention. A real-world evidence study28
Structured headache services as the solution to the ill-health burden of headache: 1. Rationale and description28
Resting-state magnetoencephalographic oscillatory connectivity to identify patients with chronic migraine using machine learning28
Repeated oxytocin prevents central sensitization by regulating synaptic plasticity via oxytocin receptor in a chronic migraine mouse model27
Association between migraine and cognitive impairment27
The chronobiology of migraine: a systematic review26
Effects of eptinezumab on self-reported work productivity in adults with migraine and prior preventive treatment failure in the randomized, double-blind, placebo-controlled DELIVER study25
Regional homogeneity alterations in multi-frequency bands in tension-type headache: a resting-state fMRI study25
Time is of the essence in headache measurement. A response to Gil-Gouveia25
Insular functional connectivity in migraine with aura25
The bidirectional temporal relationship between headache and affective disorders: longitudinal data from the HUNT studies24
Correction: Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results24
Disease- and headache-specific microRNA signatures and their predicted mRNA targets in peripheral blood mononuclear cells in migraineurs: role of inflammatory signalling and oxidative stress24
InterMiG: international differences in the therapeutic approach to migraine patients in specialized headache centers24
Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study24
Impact of the COVID-19 pandemic on migraine in Japan: a multicentre cross-sectional study24
The sensitivity to change of the cluster headache quality of life scale assessed before and after deep brain stimulation of the ventral tegmental area24
Acute prolonged motor aura resembling ischemic stroke after COVID − 19 vaccination (CoronaVac): the first case report24
Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States23
Pre-attack and pre-episode symptoms in cluster headache: a multicenter cross-sectional study of 327 Chinese patients23
Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study23
Major sex differences in migraine prevalence among occupational categories: a cross-sectional study using UK Biobank23
Premonitory symptoms in migraine: a systematic review and meta-analysis of observational studies reporting prevalence or relative frequency23
Effectiveness and acceptability of noninvasive brain and nerve stimulation techniques for migraine prophylaxis: a network meta-analysis of randomized controlled trials23
Angioarchitectural features amongst patients with unruptured brain arteriovenous malformations presenting with headache: findings from a single center retrospective review of 76 patients23
Measuring dose-related efficacy of eptinezumab for migraine prevention: post hoc analysis of PROMISE-1 and PROMISE-223
De novo headache in ischemic stroke patients treated with thrombectomy: a prospective study23
A systematic review of economic evaluations of pharmacological treatments for adults with chronic migraine22
Correction to: Medication overuse and drug addiction: a narrative review from addiction perspective22
Efficacy of erenumab and factors predicting response after 3 months in treatment resistant chronic migraine: a clinical service evaluation22
Investigation of cortical thickness and volume during spontaneous attacks of migraine without aura: a 3-Tesla MRI study22
0.10964107513428